imatinib mesylate has been researched along with Leukemia, Promyelocytic, Acute in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, ZM; Li, F; Mei, JG; Song, P; Tang, YM; Wang, LP; Yu, YP; Zhai, YP; Zhou, XG | 1 |
| Koya, J; Kurokawa, M; Morita, K; Nakamura, F; Toya, T | 1 |
| He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L | 1 |
| Druker, BJ | 1 |
| Abdul Mottalib, M; Choudhury, S; Islam, S; Khan, MA; Sultana, TA | 1 |
| Fang, H; Wang, K; Zhang, J | 1 |
| Ishizawa, J; Saya, H | 1 |
| Asou, N; Iwanaga, E; Mitsuya, H; Nanri, T | 1 |
| Chen, W; Dowell, J; Tirado, CA; Wakim, JJ | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Inokura, K; Ishizawa, K; Katsuoka, Y; Okitsu, Y; Onishi, Y; Shimosegawa, K | 1 |
| Beissert, T; Güller, S; Hoelzer, D; Li, JE; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
| Blagosklonny, MV | 1 |
| Ueda, T | 1 |
| Asano, S; Bai, Y; Chen, M; Harata, M; Iseki, T; Izawa, K; Kobayashi, S; Maruyama, K; Nagamura, F; Nakazawa, S; Ooi, J; Soda, Y; Sugita, K; Takahashi, S; Takahashi, TA; Takizawa, T; Tani, K; Tojo, A; Tomonari, A; Tsuji, T; Uchimaru, K | 1 |
| Chen, LJ; Chen, SJ; Zhou, GB | 1 |
| Chen, SJ; Zhao, WW | 1 |
| Ikeda, A; Moore, TB; Sakamoto, KM; Shankar, DB; Tamanoi, F; Watanabe, M | 1 |
| Hayashi, Y | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Ates, H; Pehlivan, M; Sercan, HO; Sercan, Z; Simsek, O | 1 |
| Avalos, JC; Foncuberta, MC; Tartas, NE | 1 |
| Scheinberg, DA | 1 |
| Garattini, E; Gianni', M; Kalaç, Y; Ponzanelli, I; Rambaldi, A; Terao, M | 1 |
8 review(s) available for imatinib mesylate and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome | 2018 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
[Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplastic Stem Cells; Piperazines; Pyrimidines; Translational Research, Biomedical; Tretinoin | 2009 |
[Recent progress in diagnosis of and therapy for patients with leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin | 2004 |
Molecular targets and the treatment of myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; ras Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Tretinoin | 2006 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
[Treatment of hematologic neoplasms during pregnancy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiotherapy; Rituximab | 2007 |
Old, new drugs and new, new drugs for the new millennium.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome | 2000 |
15 other study(ies) available for imatinib mesylate and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
[Acute Promyelocytic Leukemia Developed during Imatinib Therapy for Gastrointestinal Stromal Tumors].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Tretinoin | 2017 |
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin | 2014 |
Janet Rowley (1925-2013).
Topics: Benzamides; Genetics, Medical; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms; Piperazines; Pyrimidines; Translocation, Genetic; United States | 2014 |
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Topics: Adolescent; Adult; Antineoplastic Agents; Bangladesh; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin | 2008 |
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Remission Induction | 2010 |
The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Promyelocytic, Acute; Male; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic | 2012 |
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Consolidation Chemotherapy; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Promyelocytic, Acute; Male; Medication Adherence; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Translocation, Genetic | 2012 |
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Enzyme Inhibitors; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Monocytes; Oxides; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transgenes; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells; Up-Regulation | 2003 |
Do cells need CDK2 and ... Bcr-Abl?
Topics: Antineoplastic Agents; Benzamides; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Models, Biological; Piperazines; Pyrimidines | 2004 |
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Topics: Antigens, CD19; Antigens, CD34; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Cell Death; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Liposomes; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured | 2004 |
[Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Retinoic Acid; Tretinoin | 2005 |
[Arsenic treatment for leukemia: new model of human cancer target treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin | 2005 |
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |
Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin D1; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Wnt Proteins | 2007 |
Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Topics: Apoptosis; Benzamides; CD11 Antigens; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Imatinib Mesylate; Kinetics; Leukemia, Promyelocytic, Acute; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Retinoid X Receptors; Transcription Factors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2001 |